190430-68-3

Upstream product

• 190430-67-2 C₆₂H₇₂FN₅O₁₈S₅ 

Downstream Products

• 190430-69-4 4'',6''-O-benzylidene-5,2''-dideoxy-5-epi-5-fluoro-2''-oxo-1,3,2',6',3''-penta-N-tosyldibekacin 
• 190430-71-8 2''-amino-4'',6''-O-benzylidene-5,2''-dideoxy-5-epi-5-fluoro-1,3,2',6',3''-penta-N-tosyldibekacin 
• 190430-72-9 2''-amino-4'',6''-O-benzylidene-5,2''-dideoxy-5,2''-diepi-5-fluoro-1,3,2',6',3''-penta-N-tosyldibekacin 
• 190430-70-7 4'',6''-O-benzylidene-5,2''-dideoxy-5-epi-5-fluoro-2''-(methoxyimino)-1,3,2',6',3''-penta-N-tosyldibekacin 

Relevant academic research and scientific papers

Synthesis of 2'-acylamido derivatives of 2''-amino-5,2''-dideoxy-5-epi-5-fluorodibekacin and a study on the structures of 5-fluorinated dibekacin analogs by 13C NMR

Several 2N-amino-2''-deoxy and 2''-acylamido-2'-deoxy derivatives (15-21) of 5-deoxy-5-epi-5-fluorodibekacin have been prepared, introducing the 2''-NH2 group via oxidation-methoxyimination-reduction processes. The C-4 and C-6 chemical shifts in the 13C NMR spectra of several 5-fluorinated kanamycin analogs have been studied, and the difference in shifts was explained on the basis of F-5-O-4 and F-5-O-6 distances estimated by MOPAC93/PM3 calculations on related model compounds.